In an in-depth commentary for Pharmaceutical Market Europe, senior economist Jason Shafrin argues for real-world evidence (RWE) to become the “gold standard” of scientific evidence and heath technology assessments. RWE provides an opportunity to accelerate drug approval, monitor treatment safety, and appropriately price medications, Shafrin writes.
To read Jason’s complete commentary, please click here. (pg. 18-19)